PC
AZN icon

Parrish Capital’s AstraZeneca AZN Stock Holding History

Parrish Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.28M Sell
11,555
-1,278
-10% -$246K 2.03% 8
2025
Q4 		$2.36M Buy
+12,833
New +$2.25M 2.14% 7

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Parrish Capital's AZN Position: Q1 2026 in Review

Parrish Capital reduced its AstraZeneca (AZN) stake by 10% in Q1 2026, selling an estimated $246K and leaving 11,555 shares worth $2.28M. The position accounts for 2.03% of the portfolio, ranked #8.

Parrish Capital first reported a position in AZN in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.36M in Q4 2025. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Parrish Capital held 11,555 shares of AstraZeneca worth $2.28M as of Q1 2026.
  • Parrish Capital sold 1,278 AstraZeneca shares in Q1 2026, an estimated $246K.
  • AstraZeneca made up 2.03% of Parrish Capital's portfolio in Q1 2026, its #8 holding.
  • Parrish Capital first reported a position in AstraZeneca in Q4 2025 and has held it in 2 quarters since.
  • Parrish Capital's AstraZeneca position peaked at $2.36M in Q4 2025.
  • 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Parrish Capital's 13F filing for Q1 2026, filed 28 Apr 2026.